Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a progressive rare disease that, if untreated, can result in severe organ damage and death. Ravulizumab, a next-generation terminal complement inhibitor, provides immediate, complete, and sustained complement C5 inhibition. Real-world data i...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-09-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924017960 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849690475315855360 |
|---|---|
| author | Franz Schaefer Imad Al-Dakkak Katerina Anokhina David Cohen Larry A. Greenbaum Gema Ariceta |
| author_facet | Franz Schaefer Imad Al-Dakkak Katerina Anokhina David Cohen Larry A. Greenbaum Gema Ariceta |
| author_sort | Franz Schaefer |
| collection | DOAJ |
| description | Introduction: Atypical hemolytic uremic syndrome (aHUS) is a progressive rare disease that, if untreated, can result in severe organ damage and death. Ravulizumab, a next-generation terminal complement inhibitor, provides immediate, complete, and sustained complement C5 inhibition. Real-world data in patients with aHUS who switched to ravulizumab from eculizumab are lacking. Methods: The Global aHUS Registry is a multicenter study (NCT01522183) collecting data on adult or pediatric patients with an aHUS diagnosis, regardless of treatment. Patient characteristics, genetic data, hematological and renal parameters, clinical events (e.g., dialysis and kidney transplantation), and adverse events (AEs) were extracted from patients who switched to ravulizumab from eculizumab up to July 3, 2023. Results: Overall, 60 patients switched to ravulizumab (adult: n = 43; pediatric: n = 17); 11 patients were excluded from effectiveness and genetic analyses (N = 49; adult: n = 40; pediatric: n = 9) because they received <3 months ravulizumab treatment and/or had >1 month between eculizumab discontinuation and ravulizumab initiation. Pathogenic complement variants were identified in 11 of 49 patients (22%); the most common was a complement factor H variant (n = 5/49 [10%]). During ravulizumab treatment, 20 AEs occurred in 13 patients, with no unexpected AEs and only 3 treatment-related AEs (infusion reaction, headaches, and fatigue). No meningococcal infections or deaths were reported. No new events of dialysis, kidney transplantation, or thrombotic microangiopathy were reported. Renal and hematological parameters remained stable after switching to ravulizumab. Conclusion: This is the first real-world cohort analysis of data from patients treated with ravulizumab and reinforces the real-world safety and effectiveness data of ravulizumab in patients with aHUS who switched from eculizumab. |
| format | Article |
| id | doaj-art-13daf4d90a904443af6a7b4f7f55321e |
| institution | DOAJ |
| issn | 2468-0249 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney International Reports |
| spelling | doaj-art-13daf4d90a904443af6a7b4f7f55321e2025-08-20T03:21:18ZengElsevierKidney International Reports2468-02492024-09-01992648265610.1016/j.ekir.2024.06.020Global aHUS Registry Analysis of Patients Switching to Ravulizumab From EculizumabFranz Schaefer0Imad Al-Dakkak1Katerina Anokhina2David Cohen3Larry A. Greenbaum4Gema Ariceta5Division of Pediatric Nephrology, Heidelberg University Hospital, Heidelberg, Germany; Correspondence: Franz Schaefer, Heidelberg University Hospital, Im Neuenheimer Feld 672, Heidelberg 69120, Germany.Epidemiology, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USADivision of Pediatric Nephrology, Heidelberg University Hospital, Heidelberg, Germany; Epidemiology, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA; Global Medical Affairs, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA; Department of Medicine, Columbia University Medical Center, New York, New York, USA; Division of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA; Department of Pediatric Nephrology, Vall d'Hebron Hospital, Barcelona, SpainDepartment of Medicine, Columbia University Medical Center, New York, New York, USADivision of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USADepartment of Pediatric Nephrology, Vall d'Hebron Hospital, Barcelona, SpainIntroduction: Atypical hemolytic uremic syndrome (aHUS) is a progressive rare disease that, if untreated, can result in severe organ damage and death. Ravulizumab, a next-generation terminal complement inhibitor, provides immediate, complete, and sustained complement C5 inhibition. Real-world data in patients with aHUS who switched to ravulizumab from eculizumab are lacking. Methods: The Global aHUS Registry is a multicenter study (NCT01522183) collecting data on adult or pediatric patients with an aHUS diagnosis, regardless of treatment. Patient characteristics, genetic data, hematological and renal parameters, clinical events (e.g., dialysis and kidney transplantation), and adverse events (AEs) were extracted from patients who switched to ravulizumab from eculizumab up to July 3, 2023. Results: Overall, 60 patients switched to ravulizumab (adult: n = 43; pediatric: n = 17); 11 patients were excluded from effectiveness and genetic analyses (N = 49; adult: n = 40; pediatric: n = 9) because they received <3 months ravulizumab treatment and/or had >1 month between eculizumab discontinuation and ravulizumab initiation. Pathogenic complement variants were identified in 11 of 49 patients (22%); the most common was a complement factor H variant (n = 5/49 [10%]). During ravulizumab treatment, 20 AEs occurred in 13 patients, with no unexpected AEs and only 3 treatment-related AEs (infusion reaction, headaches, and fatigue). No meningococcal infections or deaths were reported. No new events of dialysis, kidney transplantation, or thrombotic microangiopathy were reported. Renal and hematological parameters remained stable after switching to ravulizumab. Conclusion: This is the first real-world cohort analysis of data from patients treated with ravulizumab and reinforces the real-world safety and effectiveness data of ravulizumab in patients with aHUS who switched from eculizumab.http://www.sciencedirect.com/science/article/pii/S2468024924017960atypical hemolytic uremic syndromeeculizumabreal-world dataravulizumaboutcomespatient characteristics |
| spellingShingle | Franz Schaefer Imad Al-Dakkak Katerina Anokhina David Cohen Larry A. Greenbaum Gema Ariceta Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab Kidney International Reports atypical hemolytic uremic syndrome eculizumab real-world data ravulizumab outcomes patient characteristics |
| title | Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab |
| title_full | Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab |
| title_fullStr | Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab |
| title_full_unstemmed | Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab |
| title_short | Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab |
| title_sort | global ahus registry analysis of patients switching to ravulizumab from eculizumab |
| topic | atypical hemolytic uremic syndrome eculizumab real-world data ravulizumab outcomes patient characteristics |
| url | http://www.sciencedirect.com/science/article/pii/S2468024924017960 |
| work_keys_str_mv | AT franzschaefer globalahusregistryanalysisofpatientsswitchingtoravulizumabfromeculizumab AT imadaldakkak globalahusregistryanalysisofpatientsswitchingtoravulizumabfromeculizumab AT katerinaanokhina globalahusregistryanalysisofpatientsswitchingtoravulizumabfromeculizumab AT davidcohen globalahusregistryanalysisofpatientsswitchingtoravulizumabfromeculizumab AT larryagreenbaum globalahusregistryanalysisofpatientsswitchingtoravulizumabfromeculizumab AT gemaariceta globalahusregistryanalysisofpatientsswitchingtoravulizumabfromeculizumab |